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a b s t r a c t
Background: Chromogranin A (CgA) is a biomarker for neuroendocrine tumors (NETs). The aims of this
study were to evaluate differences in measurement between the ThermoFisher Brahms CgA Kryptor
assay and the CisBio assay and to investigate the inﬂuence of patient covariates. Temperature stability of
CgA using both assays was determined.
Design and Methods: 406 patients were analyzed for serum CgA using both assays. We performed a
comparison study to determine whether several patient covariates (gender, use of protein pump
inhibitors, impaired kidney function, referral department and tumor location) inﬂuenced the results.
For the stability study, pooled serum samples were aliquoted and stored at different storage temper-
atures (room temperature, 4 1C and 20 1C) until assayed. In addition, 15 individual samples were
evaluated after storage at 4 1C using the Kryptor assay.
Results: Differences in measured concentrations between the assays were statistically signiﬁcant. Passing
& Bablok ﬁt showed ln Y(Kryptor)¼1.05 ln X(CisBio) – 0.20 with a bias of 1.0% after logarithmic
transformation. Patient covariates were not associated. Patients' sera showed variable stability for CgA
in the Kryptor assay at room temperature and 4 1C, whereas the recovery in the CisBio assay was stable at
both temperatures.
Conclusion: Differences in measured CgA concentration between the assays could not be explained by
the investigated patient covariates. Serum should be stored at –20 1C prior to determination using the
Kryptor assay.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Chromogranin A (CgA) is a member of the granin family and is an acidic glycoprotein consisting of 439 amino-acids with an
approximate molecular mass of 48 kDa. CgA is produced and stored, together with the other members of the granin family (e.g.
chromogranin B and C and other secretogranins), in large dense-core vesicles of neuroendocrine cell types. These cells can be found in the
adrenal medulla, sympathetic nerve endings, cerebral cortex, pituitary gland, gastrointestinal tract, thyroid, parathyroid glands, pancreatic
islets and lungs. Different neuroendocrine cells can process CgA differently in the cell. CgA acts as a pro-hormone which produces
biologically active peptides for a wide range of biological activity by proteolytic cleavage [1,2].
The serum concentration of CgA is a sensitive but nonspeciﬁc marker for neuroendocrine tumors (NETs). NETs are rare neoplasms
characterized by the ability to synthesize, store and secrete different peptides and neuroamines. Less than 10% of NETs are functional, that
is, functional (hormone-secreting) with speciﬁc hypersecretory symptoms/syndromes. Most are non-functional. Classiﬁcation of NETs can
be done by localization and the embryological origin of the involved organ. Foregut carcinoid tumors are found in the thymus, bronchus,
stomach, ﬁrst portion of the duodenum, pancreas and ovaries. Midgut carcinoid tumors occur in the second part of the duodenum,
small bowel and ascending colon, while hindgut tumors occur in the transverse colon, descending colon and rectum. Typically, in
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well-differentiated NETs, the CgA elevation is more pronounced and often correlated with clinical symptoms, tumor mass, differentiation
and presence of metastases [1–3]. Different tumors can release different molecular forms of CgA after post-translational processing with
difference in circulating epitopes [1,4,5]. Also, different analytical methods with possible variable antibody–epitope binding characteristics
can give different results [5–8]. Reliable quantiﬁcation of CgA is important since it is used as a marker for NETs and for long-term follow up
and treatment of the tumor.
Clinical interpretation of CgA results from different laboratories is hampered by considerable heterogeneity between available CgA
assays. In our department of Clinical Chemistry the Kryptor CgA assay was introduced to replace the CisBio ELISA because the Kryptor
assay facilitates a faster turn-around-time.
In preliminary work using randomly selected patients' samples with a request for CgA, we found a satisfactory comparison for CgA
concentrations up to 300 μg/L (range: 19–300 μg/L) with a slope of 0.99 and an intercept of –1.15 (n¼91). The difference plot of the values
obtained provided a mean difference of 0.44 μg/L (2.7%). Therefore the reference value of CgA (o98 mg/L) provided by the CisBio
manufacturer was not altered when the Kryptor assay was introduced. However, a larger bias was found at higher concentrations in NET
patients and we therefore started a large comparison study in our clinic.
Since patients' samples are often stored for some time before determination of CgA, we determined the inﬂuence of different storage
temperatures on the recovery of the CgA in the two assays.
In the present large comparison study of patients with known or suspected neuroendocrine tumors, we compare the analytical
performance of the Kryptor assay with the CisBio assay. We hypothesized that the different NET locations in patients may result in
different forms of circulating molecular CgA, which could lead to different results when measured with two assays raised against different
epitopes. Also other factors (e.g. gender, use of proton pump inhibitors) might affect the result. To our knowledge, this is the largest
published comparison study to investigate these factors.
2. Methods
2.1. Study population
In the Erasmus MC Rotterdam (ENETS centre) 406 consecutive patients were included over a nine-month period (March 2012–January
2013) from the Department of Internal Medicine (section of Endocrinology and Nuclear Medicine). In contrast to the Department of
Endocrinology, almost all patients referred from the Department of Nuclear Medicine have metastatic disease. The referral department is
therefore used as a marker for advanced disease in this study.
During this period all patient CgA concentrations were determined simultaneously with the Kryptor and CisBio assays. Patients either
had a known NET for which they were being treated, or were into follow-up or were new cases with a suspected NET submitted for
investigation.
2.2. Assays
The 29-min Kryptor assay is a sandwich immunoassay using Time-Resolved Ampliﬁed Cryptate Emission (TRACE) technology
(ThermoFisher Brahms, Hennigsdorf, Germany). TRACE technology is based on a non-radiative energy transfer between a donor
(europium cryptate) and an acceptor (XL665). The Kryptor assay facilitates automatic dilution of the sample inboard in case the default
upper range of assay linearity is reached (measuring range, including automatic dilution 7–1,000,000 mg/L). The assay uses two mouse
monoclonal antibodies. The epitope of the LK2H10 antibody has been identiﬁed as part of the amino acid sequence 250–301 [9,10].
The epitope of the monoclonal antibody PHE5 is not described in the literature. The inter-assay coefﬁcient of variation (CV) for the Kryptor
assay was 12.6% and 3.1% at 9.1 mg/L and 417.1 mg/L, respectively and the intra-assay CV of the Kryptor assay in our lab was 2.1% and 0.70%
at 48.6 mg/L and 395.2 mg/L, respectively.
The CisBio assay is a solid-phase ELISA (CisBio Bioassays, Codolet, France). Sample dilution for the CisBio assay needs to be done
manually (in the next run) after a result in the upper range is found. Performance of the CisBio assay takes 18 hours and it must be
performed in batch mode. The assay uses two monoclonal antibodies against the central domain of CgA (amino acids 145–245). For the
CisBio assay the inter-assay CV was 12% and 7% at 40 mg/L and 170 mg/L, respectively and the intra-assay CV was 4.2% and 3.7% at 100 mg/L
and 400 mg/L, respectively.
2.3. Sample collection and comparison of CgA methods
Blood samples were obtained using venepuncture technique in 7 mL vacuum collection serum-separating tubes and centrifuged within
6 h at 1000–1200g for 10 min. Serum, the recommended matrix by the manufacturer, was frozen in aliquots and kept at 20 1C before
analysis.
2.4. Stability conditions of the assays
We made two pools by mixing sera from 5–10 patients with approximately the same level of CgA. Concentrations of the pools were
80–109 mg/L and 390–529 mg/L. They were aliquoted and stored for 0, 2, 4 or 8 days at room temperature, 4 1C or 20 1C. Subsequently,
samples were stored 0–8 days at 80 1C until assayed in singlicate by either the CisBio or Kryptor assay. Because the recovery was found
to be very low (20%) for the Kryptor assay in pooled samples after 24 h at 4 1C, we duplicated the recovery data using a new serum pool at
4 1C. Additionally, 15 individual samples with a concentration range of 48–1169 mg/L were measured in singlicate at 4 1C in the
Kryptor assay.
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2.5. Covariates
Covariates investigated were gender, location of the tumor, use of proton pump inhibitor/ H2-receptor antagonist (PPI/H2RA), impaired
kidney function (estimated GFR by MDRD equation, mL/min/1.73 m2) and referral department (Internal Medicine and Nuclear Medicine).
Categorical data were partly obtained by research nurses in the outpatient clinic and from patient ﬁle research. The location of the NET
was classiﬁed according to anatomic location and functionality. PPI use and renal failure were classiﬁed as dichotomous variables.
Estimated GFR (MDRD)o60 mL/min/1.73 m2 was used as the cut-off value to deﬁne impaired kidney function.
2.6. Statistical analyses
After natural logarithm-transformation of the measurements, a normal distribution was seen in the 406 patients. A paired t-test was
performed on these data and the concordance between the assays was measured by the correlation coefﬁcient. Passing & Bablok curve
ﬁtting and a difference plot was performed. Linear regression analysis of covariates was made. For analysis of the covariate location,
we used deviation coding in which the mean difference is used as reference. The CgA stability over time and at different temperatures was
calculated as a recovery percentage of the CgA concentration at time 0. Recoveries ranging from 90% to 110% were deemed to be
acceptable.
All analyses were performed with the R statistical package (version 3.1.0, 2014; www.r-project.org). Passing–Bablok and difference plot
analysis were done in Analyse-it v2.30 (Analyse-It Software Ltd, www.analyse-it.com). Two-tailed Po0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Performance of assays
Of the 406 patients, 186 (45.8%) were female and 220 (54.2%) were male. 122 (30%) used PPI or H2RB. Measured CgA levels of the
Kryptor assay were on average higher compared to the CisBio assay (P¼0.012), Pearson's correlation 0.97. The distribution of the CgA
concentration in the patients' samples is summarized in Table 1.
When classifying patients for the covariate location, 59 patients (14.5%) were diagnosed with a NET with unknown primary. Another 22
patients (5.4%) were diagnosed with a high probability of a certain location and were classiﬁed for this speciﬁc location. Seven patients
were expected to have normal CgA concentrations since no tumor was diagnosed. One patient of these seven had an increased CgA
concentration of 4040 mg/L with the CisBio, and 3571 mg/L with Kryptor. The increased CgA level could be explained since he was using a
PPI and had impaired renal function (estimated GFR 59 mL/min/1.73 m2). This patient has known diabetes mellitus type II and is being
followed up at the endocrinology outpatient clinic. The other 6 patients with no diagnosed tumor neither used PPI nor had altered renal
function. One of these had a slightly increased CgA concentration (109 mg/L) using the Kryptor assay. All other concentrations were not
increased.
Five patients were diagnosed with a tumor other than NET. Of the 394 remaining patients with a diagnosed NET, 138 patients (35.0%)
were found to have non-increased CgA levels in the CisBio assay. For Kryptor this ﬁgure was 135 (34.3%).
Eighty-one patients with foregut tumors (n¼105) had tumors of pancreatic origin. The other tumors were located in lung (n¼11),
stomach (n¼4), duodenum (n¼4), thymus (n¼3) or ovary (n¼2). Midgut tumors (n¼158) were located in the small bowel or ascending
colon. Hindgut tumors (n¼16) were located in the transverse or descending colon or the rectum. Of the functional NETs (n¼31), most
were diagnosed with gastrinoma (n¼11). Other functional NETs were diagnosed as insulinoma (n¼10), glucagonoma (n¼4), VIPoma
(n¼3) or a combination of these (n¼3). Thirteen (3.2%) patients were diagnosed with paraganglioma. Other patients had pheochromo-
cytoma (n¼6), medullary carcinoma of the thyroid (n¼4), carcinoid of the adrenal medulla (n¼1) and NET of the cranial clivus (n¼1).
Since in clinical practice CgA measurement is performed both in patients with and without NETs, all 406 patients were included in the
comparison between the CisBio and Kryptor assays. The Passing & Bablok ﬁt of the values showed a slope of 1.05 with 95% CI of 1.03–1.07
and an intercept of 0.20 with 95% CI of 0.28 to 0.12 (Fig. 1A). The difference plot (N¼406) showed an overall positive bias of 1.0%
with a 95% CI of 0.0–1.9% (Fig. 1B). We found that, in the concentration range of the natural logarithm means 5–6 (corresponding to
150–400 mg/L, n¼95), a bias towards higher concentrations with the Kryptor assay is seen compared to the CisBio assay. No signiﬁcant
covariate associations were found in this subpopulation. Sixteen patients with much lower Kryptor values compared to those determined
by the CisBio method also showed similar characteristics to the overall study population.
Gender was not associated with the difference between CisBio and Kryptor measurements (P¼0.18), neither was PPI use (P¼0.60),
impaired renal function (P¼0.66) or referral department (P¼0.21). Also, tumor location was not associated.
Table 1
Descriptive statistics in 406 (suspected) NET patients.
CisBio assay Kryptor assay
CgA (mg/L) CgA (mg/L)
Mean 1571 1862
Median 148.5 160.5
Range 5–137,000 6–143,100
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3.2. Stability of the assays
Storage at –80˚C showed good recoveries of 99.9–104.5% after 24 h. Figs. 2 and 3 show results of the stability of CgA over 8 days using
pooled samples.
The Kryptor assay shows a recovery of 94–97% after 8 h at 4 1C. After 24 h, however, recovery at 4 1C decreased to 80–81% and at day
8 had fallen to 13–20%. At room temperature, the recoveries were 98.0–98.2% after 24 h, decreasing to 62.6–76.3% at day 8. At 20 1C, a
good recovery of 95.2–95.4% was found at day 8 (Fig. 2).
The CisBio showed a recovery of 91.3–100.8% at day 8 at both 4 1C and 20 1C. At room temperature this was 79.2–116.0% (Fig. 3).
Since a very low CgA recovery was found in pooled sera with the Kryptor assay after storage at 4 1C, additional measurements in
individual sera were performed. Fig. 4 shows recoveries of 15 unpooled sera with baseline concentrations of 48–1169 mg/L, stored for seven
days at 4 1C and measured by the Kryptor assay. Here, variations in recovery ranging from 36.8% to 102.8% at 24 h and o8.6–97.4% after
seven days were found.
4. Discussion
In this study, we performed a large comparison study in NET patients using the Kryptor CgA assay and CisBio assay.
Overall, Kryptor measured signiﬁcantly higher levels of CgA compared to CisBio. To our knowledge, this is the largest population in
which the covariates tumor location, gender, use of PPI, impaired kidney function and referral department (endocrinology or nuclear
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Fig. 1. (A) Comparison between CisBio and Kryptor CgA assay (Passing & Bablok curve ﬁt, all samples). y¼1.05–0.20x. (B) Difference plot of Kryptor and CisBio CgA
measurements (all samples). Bias of þ1.0% (95% CI=0.0–1.9).
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medicine) have been investigated. We hypothesized that patient dependent covariates could affect the molecular structure of excreted
CgA molecules. In this way different assays could detect different levels of CgA. PPI usage has been shown to increase CgA levels in several
commercial assays [11–13]. In one study, use of PPI did not give alterations in measured concentrations of the different region-speciﬁc
assays [8]. Molina et al. [6] showed in a subgroup of patients without cancer that different assays can be inﬂuenced differently by renal
failure. Stridsberg et al. [8] showed in a small study population with NETs that for an individual patient, impaired kidney function can
inﬂuence immunoreactivity in a particular region on the CgA molecule (amino acids 17–38).
In our study we found no associations for the covariates studied. In healthy persons, Dittadi et al. [14] also found no association with
gender using the CisBio assay. However, Braga et al. [15], using the Kryptor CgA assay, found higher values in women compared to men.
Fig. 3. Recoveries of CgA with the CisBio assay at different temperature conditions in pooled samples. Percentages shown in the legend are recoveries on the last day of
storage. Initial sample concentrations are also shown.
Fig. 2. Recoveries of CgA with the Kryptor assay at different temperature conditions in pooled samples. Percentages shown in the legend are recoveries on the last day of
storage. Initial sample concentrations are also shown.
Fig. 4. Recoveries of CgA with the Kryptor assay in 15 individual (unspooled) samples stored at 4 1C. Percentages shown are the highest and lowest recovery in these
samples. The initial CgA concentrations for these samples are also shown.
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Different endocrine cell types process the CgA molecule differently [16]. In the intestine most enterochromafﬁn cells are positive for
N-terminal and mid-portion antibodies, whereas C-terminal antibodies do not give rise to immunoreactivity. Gastrin cells display
immunoreactivity to both N- and C-terminal antibodies [10]. Also in human endocrine pancreas, different cell types show different
distribution patterns of region speciﬁc antibody binding [9]. CgA is an early marker of NETs in the foregut and the midgut [1]. Lower
concentrations were found in hindgut tumors and other NETs. NETs of unknown primary site are diverse tumors with variable clinical
behavior, predicted by tumor grade or differentiation. Their reported prevalence is 13% of all NETs, which is likely to be an underestimate
due to reporting bias and assignment of tumors to suspected but unconﬁrmed sites [17]. In our study population 14.5% of the patients
were found to have a NET of unknown primary. Another 5.4% had a NET of unknown primary, but had a high probability of a certain
location mentioned in their patient ﬁle, mostly midgut tumors. We chose to classify these patients according to the most probable location
mentioned. This could have introduced misclassiﬁcation but this misclassiﬁcation would be larger if this 5.4% was added to the NET
unknown primary group. We hypothesized that tumor location could be associated with differences between the assays since different cell
types process CgA differently. However, this was not found in our study with a large population of NET patients.
A recent study compared the Kryptor and CisBio CgA assay in 78 patients suspected of NETs [13]. The authors reported a mean
difference of 10.1 mg/L, with CisBio giving higher concentrations compared to Kryptor. However, we found higher concentrations measured
with the Kryptor assay as compared to the CisBio assay, mainly in the concentration range of the natural logarithm means 5–6
(corresponding to 150–400 mg/L). Patient covariates were not different in this range. Because our population included not only patients
suspected of a NET, but also patients for follow-up or under treatment, CgA produced by the tumors after post-translational modiﬁcations
could differ in our population compared to the population of 78 patients suspected of NETs in the study of Popovici et al [13]. Because the
untransformed data was not normally distributed, only log transformed data should be used in the analysis. Consequently, we cannot
compare directly the mean difference we found with the study of Popovici et al.
Interestingly, signiﬁcant differences can occur in assays using the same antibodies, but with a different assay architecture. This was
found in a study by Dittadi et al. [18], in which the CisBio ELISA was compared to the CisBio IRMA. The ELISA showed signiﬁcant
underestimation compared to IRMA in plasma EDTA samples.
Optimal shipment and storage conditions are important for reliable CgA determinations. Using the CisBio assay, CgA in serum is stable
at both 4 1C and 20 1C. Although the CgA is stable at 20 1C using the Kryptor assay, the assay showed a low recovery in pooled samples
after storage at room temperature and even lower at 4 1C. This is probably due to variation in stability in individual patient samples,
as shown in Fig. 4. Similar results were found for storage at 4 1C using a recently launched ELISA, EDI KT-820 assay (Epitope Diagnostic Inc.
San Diego, USA) (de Rijke, unpublished results). Our data are in agreement with a recent study showing an average decrease of Kryptor
CgA in individual samples of 15.6% and 44.0% after 24 and 48 h at 4 1C, respectively [19].
Hypothetically, epitope exposure is different at the temperatures studied because of CgA polymerization, folding or degradation by
proteinases. The CgA molecule may start to fold at temperatures of 2–8 1C and the antibodies used in the assay may be prevented from
binding to their epitope on the irreversible folded structure. Therefore the CgA molecule may not be detected by the assay. If this is a
continuous process, this will result in a decreasing concentration over time (ThermoFisher, personal communication). Intracellular CgA
can form dimers or tetramers with chromogranin B in secretion vesicles [20]. Hypothetically, this could also occur after blood sampling
and result in decreased availability of the epitope. Less CgA degradation might be expected at lower concentrations of calcium ions since
endoproteinase activity depends on Ca2þ [21]. Another explanation might be the formation of irreversible CgA–antibody complexes at
lower temperatures, as has been described for lactate dehydrogenase (LD) which showed this property at 0–7 1C due to a cold-induced
conformational change in the LD tetrameric molecule [22]. When stored at 75 1C or room temperature for 24 h, no decrease in LD
activity was seen. Cold denaturation could be another explanation of our ﬁndings, but this is unlikely since, for most studied proteins,
cold-induced denaturation temperature lies well below the freezing point of water [23,24].
5. Conclusion
Our study showed that the CisBio assay can conveniently be replaced by the Kryptor assay with the advantage of having a lower
coefﬁcient of variation, higher throughput and a better turn-around time. However, storage and shipping conditions can have a major
inﬂuence on CgA concentrations. Serum should be stored at 20 1C using the Kryptor assay. Storage at room temperature and 4 1C should
be avoided when using the Kryptor assay since rapid decrease in recovery can occur in individual serum samples.
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